Overview

Relative Bioavailability Study for GSK1838262 (Gabapentin Enacarbil)

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative drug concentrations achieved with different formulations of GSK1838262 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
XenoPort, Inc.